Michael Barbella, Managing Editor01.19.23
RapidAI has received U.S. Food and Drug Administration 510(k) clearance for the latest release of Rapid ICH, an intracranial hemorrhage (ICH) triage and notification tool that boasts a 97% sensitivity and 100% specificity.
This new release further strengthens RapidAI's hemorrhagic solution—technology that supports physicians’ ability to accurately and comprehensively address intracranial hemorrhagic management. While Rapid ICH uses artificial intelligence to quickly analyze non-contrast CT (NCCT) scans and notify clinicians of possible hemorrhage, Rapid Hyperdensity then provides physicians with a more refined view by automatically quantifying and characterizing tissue to identify the location and volume of hyperdense regions. Combined, the two products represent a premier hemorrhagic management solution, according to the company.
“With the sheer number of CT scans performed daily, even relatively low rates of false positive ICH notifications can be disruptive and contribute to notification fatigue,” said Dr. David Fiorella, M.D., Ph.D., a neuroradiologist at Stony Brook Medicine. “The latest release of Rapid ICH essentially eliminates false positives and gives physicians a high degree of confidence to make critical decisions about patients with acute brain hemorrhages. This degree of specificity is a remarkable achievement.”
Key benefits of Rapid ICH:
This new release further strengthens RapidAI's hemorrhagic solution—technology that supports physicians’ ability to accurately and comprehensively address intracranial hemorrhagic management. While Rapid ICH uses artificial intelligence to quickly analyze non-contrast CT (NCCT) scans and notify clinicians of possible hemorrhage, Rapid Hyperdensity then provides physicians with a more refined view by automatically quantifying and characterizing tissue to identify the location and volume of hyperdense regions. Combined, the two products represent a premier hemorrhagic management solution, according to the company.
“With the sheer number of CT scans performed daily, even relatively low rates of false positive ICH notifications can be disruptive and contribute to notification fatigue,” said Dr. David Fiorella, M.D., Ph.D., a neuroradiologist at Stony Brook Medicine. “The latest release of Rapid ICH essentially eliminates false positives and gives physicians a high degree of confidence to make critical decisions about patients with acute brain hemorrhages. This degree of specificity is a remarkable achievement.”
Key benefits of Rapid ICH:
- Detects suspected ICH as small as 0.4ml in volume
- Prioritizes cases within the radiology worklist
- Streamlines decision making by automatically sending notifications of suspected ICH to PACS, email, and the Rapid mobile app
- Drastically reduces the number of false positives, addressing concern of “notification fatigue” for physicians